HAVN Life Sciences Inc. reported earnings results for the third quarter and nine months ended January 31, 2022. For the third quarter, the company reported sales was CAD 0.023025 million. Net loss was CAD 2.19 million compared to CAD 13.16 million a year ago. Basic loss per share from continuing operations was CAD 0.6 compared to CAD 5.1 a year ago.
For the nine months, sales was CAD 0.060094 million. Net loss was CAD 11.08 million compared to CAD 19.38 million a year ago. Basic loss per share from continuing operations was CAD 2.7 compared to CAD 12.3 a year ago.